Loading
Giving six cycles of docetaxel at the start of hormone therapy for metastatic prostate cancer lengthened survival by over a year in men with high-volume disease, the first trial to show that early chemotherapy helps.
Phase 3 trial of 790 men with metastatic hormone-sensitive prostate cancer randomised to androgen deprivation alone or with six cycles of docetaxel.
Median overall survival was 57.6 versus 44.0 months (hazard ratio 0.61) overall, and 49.2 versus 32.2 months in high-volume disease; long-term follow-up showed no benefit in low-volume disease.
Docetaxel with androgen deprivation is a standard for high-volume metastatic hormone-sensitive prostate cancer, now usually combined with an androgen receptor pathway inhibitor as triplet therapy.
The answer to a question three individual trials could not answer on their own, and the reason docetaxel with androgen deprivation became standard for metastatic hormone-sensitive disease. It also stopped a widely used bone drug being credited with a survival effect it does not have.
A negative trial that was later overturned, and a standing argument for pooling individual trials rather than acting on the first one to report. It is also the reason the distinction between high-volume and low-volume metastatic disease is written into guidelines.
The end of therapeutic nihilism in castration-resistant prostate cancer. It is also the trial that set the field's expectation of what a positive result looks like in this disease: a hazard ratio near 0.75 and a median gain measured in months, not years.
Shares GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer, STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares CHAARTED (E3805), STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine.
Shares TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, New England Journal of Medicine, Prostate cancer.
Shares CHAARTED (E3805), Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis, TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, Prostate cancer.